The NHS has approved mirvetuximab soravtansine (Elahere) for folate receptor-alpha–positive, platinum-resistant epithelial cancers of the ovary, peritoneum, or fallopian tube, marking the NHS’s first such ovarian cancer approval in 20 years.

Patients and clinicians describe the treatment as potentially improving quality of life, with notably fewer debilitating side effects than conventional platinum chemotherapy and a better ability to live normal lives during treatment.

Clinical trial data show the drug targets FRα-expressing tumors, is given as an infusion every three weeks, and can extend average overall survival by about four months versus chemotherapy, with a higher response rate (about 37% of tumors shrinking by at least 30% versus 16% with chemotherapy).

The treatment delayed disease progression and was developed as a targeted antibody–drug conjugate, designed to deliver cancer-killing agents directly to tumor cells.

Experts and patient advocates call the decision a landmark that could improve outcomes for hundreds of women facing hard-to-treat disease.

The NHS decision follows NICE final draft guidance and a new commercial arrangement with AbbVie, aiming to provide an additional option when platinum resistance has developed.

Trial participant Jenny Green described minimal side effects and shrinking nodules, signaling a positive real-world response to the drug.

Patients like Patricia from north London report dramatic personal improvements, enabling continued participation in events and family activities.

The article includes quotes from patient advocates and clinicians highlighting optimism, potential quality-of-life benefits, and the ongoing need for effective ovarian cancer options.

Public reaction from NHS England underscores the therapy as a significant advancement in NHS cancer care.

Trial leader Dr. Rowan Miller emphasizes improved survival and tolerability on the NHS compared with traditional chemotherapy.

The decision was informed by input from patient groups and clinicians about the unmet need in platinum-resistant ovarian cancer.